Tourmaline Bio

Check out Scrip’s 2025 Predictions, featuring insights from our Co-Founder and CEO, Dr. Sandeep Kulkarni. Dr. Kulkarni highlights how non-invasive imaging technologies are positioned to transform cardiometabolic drug development. Advancements in AI-powered cardiac imaging, ultrasounds, and CT angiography are refining trial designs, enabling earlier, precise insights into cardiovascular risk, and driving tailored treatments. Thank you to Scrip for including this perspective on driving progress in addressing the global burden of cardiovascular disease. Read more here: https://bit.ly/43bQqBd

It was great to see this piece in Ophthalmology Times about thyroid eye disease (TED) and the treatment landscape, including Tourmaline’s spiriTED clinical trial that is investigating pacibekitug (also known as TOUR006), a long-acting, fully-human anti-IL-6 monoclonal antibody. Thank you, Ophthalmology Times and David Hutton, for spotlighting this important perspective. Read the full article here: https://bit.ly/408rVBY

This Heart Health Month, we’re shining a light on the vital connection between cardiovascular inflammation and cardiovascular disease. Despite advances in treatment, cardiovascular disease remains the leading cause of death globally, resulting in an estimated 20 million deaths annually. Research shows inflammation plays a critical role in the development and progression of cardiovascular diseases, including ASCVD. Tourmaline is committed to addressing this unmet need by advancing innovative therapies that target IL-6-driven inflammation. Learn more about how Tourmaline is working to redefine care in cardiovascular disease: https://bit.ly/3C9VxqB

Tourmaline CEO & Co-Founder Sandeep Kulkarni sat down with PharmaVoice to discuss the evolving cardiovascular landscape and the critical role of IL-6 inhibition in addressing residual inflammatory risk. With inflammation increasingly recognized as a key driver of cardiovascular disease, innovation in this space is more important than ever. Read the full article: https://bit.ly/40Y9T5W

Cardiovascular disease remains the number one killer of women worldwide. On National Wear Red Day, we recognize the importance of advancing research to change this statistic. “Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women” was presented as a late-breaker at the European Society of Cardiology Congress in London and published simultaneously in the New England Journal of Medicine in August 2024 by Dr. Paul Ridker, Director of the Center for Cardiovascular Disease Prevention Eugene Braunwald Professor of Medicine, Harvard Medical School, and member of Tourmaline’s Cardiovascular SAB. The landmark analysis of the Women’s Health Study demonstrated that hs-CRP, LDL cholesterol, and lipoprotein(a) levels among initially healthy U.S. women were highly predictive of incident cardiovascular events during a 30-year period. Moreover, hs-CRP was the strongest predictor among the three biomarkers, with the highest quintile associated with a 70% increased risk of myocardial infarction, coronary revascularization, stroke, or death from cardiovascular causes. Join us in wearing red today and supporting the fight against cardiovascular disease. Learn more: https://bit.ly/3PydWk8

Tourmaline will be participating in the Guggenheim Securities SMID Cap Biotech Conference on February 5! Join us as we share insights during our fireside chat, highlighting our commitment to developing transformative medicines for immune and inflammatory diseases. Registration for the fireside is accessible on our website, and a replay will be available if you can’t make the live presentation: https://bit.ly/427wQ90

Tourmaline CV SAB member and CEO of Sequoia Genetics, Dr. Dipender Gill, Group Leader at the University of Cambridge and the Lead Statistician at Sequoia Genetics, Dr. Stephen Burgess, our SVP of Medical Research, Dr. Emil deGoma, and fellow industry experts co-authored new research that explores genetic insights that enhance our understanding of cardiovascular disease.     The study demonstrates that individuals who carry genetic variants of IL-6 pathway downregulation have a lower risk of abdominal aortic aneurysm, supporting IL-6 inhibition as a potential therapy.     Read more: https://bit.ly/427wQ90  

It was great connecting with biotech and pharma leaders committed to healthcare innovation at #JPMWeek.    The insights and discussions reinforced our mission to develop transformative medicines for patients with immune and inflammatory diseases like atherosclerotic cardiovascular disease (ASCVD), abdominal aortic aneurysm (AAA) and thyroid eye disease (TED).    Thank you to everyone who connected with us—your shared vision drives us forward. #JPM25 J.P. Morgan 

We are honored to welcome Dr. Paul M. Ridker, a luminary in the field of cardiovascular disease research and drug development, to Tourmaline’s Cardiovascular Scientific Advisory Board.  Dr. Ridker has led a paradigm shift in the understanding of atherosclerotic cardiovascular disease (ASCVD), highlighting the critical importance of inflammation, and in doing so, has impacted international guidelines for the diagnosis, treatment, and prevention of ASCVD. Dr. Ridker will provide invaluable strategic guidance as we await the results from our Phase 2 TRANQUILITY trial and prepare for the expected future development of pacibekitug to reduce inflammation in cardiovascular diseases. Read more:  https://bit.ly/3Wd4nLg  

We are honored to welcome Dr. Paul M. Ridker, a luminary in the field of cardiovascular disease research and drug development, to Tourmaline’s Cardiovascular Scientific Advisory Board.  Dr. Ridker has led a paradigm shift in the understanding of atherosclerotic cardiovascular disease (ASCVD), highlighting the critical importance of inflammation, and in doing so, has impacted international guidelines for the diagnosis, treatment, and prevention of ASCVD. Dr. Ridker will provide invaluable strategic guidance as we await the results from our Phase 2 TRANQUILITY trial and prepare for the expected future development of pacibekitug to reduce inflammation in cardiovascular diseases. Read more:  https://bit.ly/3Wd4nLg